MediciBioㅣ메디치바이오

Oligonucleotide-based or peptide-based drugs are rapidly eliminated from blood circulation after administration, attributable to their short in vivo half-lives; therefore, large amount of drug administration is necessary to show sufficient in vivo efficacy. Our Medici Peptide is developed to efficiently bind to albumin in vivo, and Medici Peptide-Drug Conjugate (MDC) can therefore increase retention time of oligonucleotide or peptide in blood circulation resulting in enhanced efficacy, and further maintain long-term in vivo efficacy by steady release of drugs from the biodegradable linker.

MediciBIO’s next-generation LNP platform leverages proprietary ionizable lipids to overcome the limitations of conventional LNP technologies, enabling local or systemic delivery with improved performance.

Advanced local delivery LNP technologies enabling the development of safe and effective mRNA vaccines

MediciBio’s Local Delivery LNP technology is engineered to remain at the injection site following intramuscular (IM) administration, minimizing systemic circulation. By limiting LNP distribution, this approach significantly reduces systemic inflammatory responses (reactogenicity) often associated with conventional mRNA vaccines.

This localized delivery advantage enables the development of safer and more targeted mRNA-based solutions — from infectious disease and cancer vaccines to therapeutics for localized conditions such as joint disorders

Pioneering systemic delivery LNP technologies for the development of mRNA therapeutics requiring repeated administration

MediciBio’s Systemic Delivery LNP is designed to overcome one of the key challenges of conventional systemic LNPs—immune activation and reduced efficacy upon repeated dosing. Following intravenous (IV) administration, this advanced LNP minimizes immunogenicity, enabling consistent performance across multiple doses.

With its repeat-dose profile, it is ideally suited for the development of mRNA and siRNA-based gene therapies, mRNA-encoded antibodies, and in vivo CAR therapies

MediciBIO’s proprietary targeting LNP platform features innovative passive and active targeting strategies, enabling efficient delivery to a wide range of tissues and cell types.

Novel passive targeting LNP platforms utilizing proprietary targeting lipids for organ-specific biodistribution

MediciBio’s Organ Targeting LNP technology, powered by Medici Targeting Lipid, enables passive and selective delivery to specific tissues.

Notably, it promotes targeted distribution to the spleen, a central immune organ, making it highly suitable for the development of mRNA and siRNA-based immunotherapies and immunosuppressants.

Innovative active targeting LNP platforms, leveraging proprietary physical ligation of diverse antibodies or aptamers to target specific cancer or immune cells

MediciBio’s Active Targeting LNP technology employs a range of targeting ligands—such as aptamers or antibodies—without chemical synthesis process, to enable gene-loaded LNPs to selectively bind to target cells and enhance intracellular delivery.

This platform supports precise targeting of various cancer types, including HCC, NSCLC, TNBC, PDAC, and GC, as well as immune cells such as T cells, monocytes, macrophages, and NK cells.

With its versatile targeting capability, it offers strong potential for the development of next-generation mRNA and siRNA-based cancer therapies, immunotherapies, and in vivo CAR therapies.